AGMB Latest Press Releases

-- October 13, 2026 --

Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease Globe Newswire 4:05 PM

-- October 8, 2026 --

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation Globe Newswire 4:05 PM

-- October 1, 2026 --

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease Globe Newswire 6:30 AM

-- September 14, 2026 --

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study Globe Newswire 4:05 PM

-- September 11, 2026 --

Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Globe Newswire 4:05 PM

-- September 3, 2026 --

Agomab to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

-- August 10, 2026 --

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Globe Newswire 4:07 PM

-- August 6, 2026 --

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook Globe Newswire 4:01 PM

-- June 23, 2026 --

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease Globe Newswire 4:05 PM

-- May 27, 2026 --

Agomab Announces Results of Annual General Meeting Globe Newswire 5:00 AM

Market Data Delayed 15 Minutes